Stocks Health care LBRX
NASDAQ · Health careLB Pharmaceuticals Inc (LBRX)
It posted a net loss of $141.2M. In fiscal 2025 capital spending exceeded operating cash flow by $35.3M. At September 30, 2026 it held $215.1M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 5, 2026.
Key facts about LB Pharmaceuticals Inc
- Net worth
- LB Pharmaceuticals Inc has a market value (market cap) of $1.5B at the latest share price, and shareholders' equity of $417.6M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Cash flow
- In fiscal 2025 operations used $35.2M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 5, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- LB Pharmaceuticals Inc's next report is expected around March 25, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What LB Pharmaceuticals Inc does
LB Pharmaceuticals Inc is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker LBRX.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$25.2M | -$3.13 | -$35.3M |
| 2025 | n/a | -$63.1M | -$176.15 | -$53.8M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What LB Pharmaceuticals Inc has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 5, 2026
- November 5, 2026
- October 13, 2026Passive stake changed SCHEDULE 13G/A
- October 1, 2026Form POS AM filing POS AM
- October 1, 2026
- September 15, 2026Executive or director change8-KLB Pharmaceuticals appointed Susan G. Kozauer, M.D. as Chief Medical Officer effective September 14, 2026.
- September 3, 2026
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 11, 2026
- August 11, 2026
Insider trades
What the people running LB Pharmaceuticals Inc did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
Who owns LBRX
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Deep Track Capital, LP13D, may seek influence with 3 related filers | 11.7% | February 10, 2026 |
| RA Capital Management, L.P.13G, passive with 3 related filers | 8.7% | February 17, 2026 |
| Commodore Capital LP13G, passive with 3 related filers | 6.8% | May 15, 2026 |
| Pontifax Management 4 G.P. (2015) Ltd.13D, may seek influence with 3 related filers | 6.3% | September 25, 2025 |
| Caligan Partners LP13G, passive with 1 related filers | 5% | May 15, 2026 |
| TCG Crossover GP II, LLC13G, passive with 2 related filers | 5% | August 14, 2026 |
| Trails Edge Capital Partners, LP13G, passive with 2 related filers | 5% | December 31, 2025 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 115 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Deep Track Capital, LP | 3,352,804 | 0 |
| BlackRock, Inc. | 2,734,305 | +263,460 |
| RA Capital Management, L.P. | 2,208,604 | 0 |
| Nantahala Capital Management, LLC | 2,105,788 | +1,052,894 |
| Trails Edge Capital Partners, LP | 1,523,022 | +203,660 |
| Jpmorgan Chase & Co | 1,497,293 | +69,725 |
| Commodore Capital LP | 1,500,000 | 0 |
| TCG Crossover Management, LLC | 1,447,310 | -392,179 |
| Caligan Partners LP | 1,438,070 | 0 |
| Spruce Street Capital LP | 1,376,159 | 0 |
| Vanguard Capital Management LLC | 971,165 | +76,512 |
| Balyasny Asset Management L.P. | 921,471 | -2,223 |
| Alyeska Investment Group, L.P. | 863,947 | 0 |
| Vivo Capital, LLC | 800,000 | 0 |
| Nan Fung Group Holdings Ltd | 630,657 | 0 |
| Geode Capital Management, LLC | 612,793 | +94,565 |
| State Street Corp | 602,028 | +97,655 |
| Logos Global Management LP | 585,000 | -330,000 |
| Goldman Sachs Group Inc | 576,456 | +212,657 |
| Jennison Associates LLC | 540,902 | +2,686 |
Insiders
Questions about LBRX
What does LB Pharmaceuticals Inc do?
LB Pharmaceuticals Inc is a company in the Health care sector, listed on NASDAQ as LBRX. Its shares trade on NASDAQ under the ticker LBRX.
What is LB Pharmaceuticals Inc's net worth?
LB Pharmaceuticals Inc has a market value (market cap) of $1.5B at the latest share price, and shareholders' equity of $417.6M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is LB Pharmaceuticals Inc profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $141.2M.
When did LB Pharmaceuticals Inc last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 5, 2026. It covers the period to September 30, 2026.
When is LB Pharmaceuticals Inc's next earnings report?
LB Pharmaceuticals Inc's next report is expected around March 25, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare LBRX with
Follow LBRX
Get an email when LB Pharmaceuticals Inc files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values LB Pharmaceuticals Inc tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.